Post-Covid Syndrome Cohort
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 750
- 试验地点
- 1
- 主要终点
- Create a patient cohort
研究概览
简要总结
SARS-CoV2 pneumonia has been a global public health emergency since 2020. The prevalence of the disease is particularly high with more than 500 million cases worldwide (7.5 million in France) since the emergence of the virus.
A substantial proportion of patients with SARS-Cov2 infection present persistent symptoms long after the acute infection. This is independent of the degree of severity of the SARS-Cov2 infection.
These symptoms can affect the quality of life and impede the return to work. While the majority of symptoms progress favourably with outpatient care, some persist and/or are particularly severe, justifying expert and multidisciplinary care.
This investigation aim to create a clinical database of patients with complex and/or severe post-CoviD and study blood markers what could predict the disease and orientate new ways of treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients who have joined the Epsilon care pathway since its opening in February 2022, i.e.:
- •Patients with post-Covid syndrome referred to the Epsilon sector from the city medicine:
- •Patient with documented SARS-Cov2 pneumonia
- •With persistent and severe symptoms beyond 4 weeks or complex or disabling symptoms beyond 3 months
- •Patient over 18 years old.
- •Post-hospital sector:
- •Patient with documented SARS-Cov2 pneumonia
- •Hospitalized for oxygen therapy (at least 48h)
- •Not having a referring pulmonologist
- •Not institutionalized
- •With a life expectancy of more than 6 months.
排除标准
- •Patient refusing that this data to be used for research purposes (objection form).
- •Patient with untreated comorbidities
结局指标
主要结局
Create a patient cohort
时间窗: Once a year
Creation of a retrospective and prospective cohort combining: * Collection of clinical and paraclinical data, scores, and scales. * Prospective monitoring of quality of life, other scores as needed. Cross-referencing of clinical data with the results of cellular and molecular analyzes on lymphocytes blood cells, which will be carried out (part carried out by Inserm). by INSERM U1111 as part of the European HERVCOV project.
次要结局
- Identify new research pathway to improve Post-Covid syndrome knowledge(12 month)
- Biological analyses to find new molecular targets (biomarkers)(12 month)